Groupe Francophone des Myelodysplasies
47
4
12
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
8.5%
4 terminated/withdrawn out of 47 trials
85.7%
-0.8% vs industry average
6%
3 trials in Phase 3/4
4%
1 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (47)
Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
Role: lead
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Role: lead
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
Role: lead
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Role: lead
French Registry of First-line Treatment of Acute Promyelocytic Leukemia
Role: lead
Momelotinib in VEXAS Syndrome
Role: lead
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
Role: collaborator
Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)
Role: lead
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
Role: lead
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS
Role: lead
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome
Role: lead
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
Role: lead
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
Role: lead
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Role: collaborator
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Role: lead
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia
Role: collaborator
Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Role: lead
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Role: lead
A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders
Role: lead
CPX-351 in Higher Risk Myelodysplastic Syndromes
Role: lead